业绩总结 - 2022年第三季度总收入为4780万美元，同比增长21%[15] - MRD业务收入为1590万美元，同比增长26%[15] - 免疫医学业务收入为2360万美元，同比增长18%[15] - 2022年全年收入指导范围为1.85亿至1.90亿美元[16] - 2022年归属于Adaptive Biotechnologies Corporation的净亏损为45,281千美元，2021年为55,903千美元[26] - 2022年调整后EBITDA为（25,868）千美元，2021年为（41,059）千美元[26] - 2022年9月30日的净亏损为160,063千美元，2021年为145,846千美元[26] 用户数据 - 2022年第三季度测试交付量增长52%[7] - 订单账户增加53%至403个[7] - 2022年第三季度MRD和免疫医学业务分别占总收入的47%和53%[16] 未来展望 - 预计2025年实现正的调整后EBITDA[6] - 预计2026年现金流平衡[6] - 预计2022-2027年收入年复合增长率（CAGR）为20-30%[20] - 预计2023年现金流为0[20] - 预计近期MRD贡献将更高[20] - 预计现金储备可维持超过3年[20] - 预计运营支出将保持低增长[20] 新产品和新技术研发 - 预计clonoSEQ的平均销售价格将每年增长中个位数[8] 融资与资金状况 - 公司完成了与OrbiMed的2.5亿美元非稀释性特许权融资[6] - 预计2022年第四季度现金消耗低于5000万美元[16]

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Karina Calzadilla - Head, IR Chad Robins - Co-Founder, CEO Tycho Peterson - CFO Harlan Robins - Chief Scientific Officer Nitin Sood - Head of MRD Sharon Benzeno - Head, Immune Medicine Conference Call Participants David Westenberg - Piper Sandler Operator Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies Third Quarter Financial Results Conference ...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q2 2022 Results Conference Call August 3, 2022 4:30 PM ET Company Participants Karina Calzadilla - Head, IR Chad Robins - Co-Founder, CEO Tycho Peterson - CFO Nitin Sood - CCO, MRD Sharon Benzeno - Head, Immune Medicine Conference Call Participants Brian Weinstein - William Blair Daniel Brennan - Cowen & Company David Westenberg - Piper Sandler Derik De Bruin - Bank of America Elizabeth Webster - Goldman Sachs Mark Massaro - BTIG Yuko Oku - Morgan Stanley ...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Karina Calzadilla - Vice President of Investor Relations Chad Robins - Chief Executive Officer and Co-Founder Kyle Piskel - Interim Chief Financial Officer Sharon Benzeno - Chief Commercial Officer, Immune Medicine Nitin Sood - Chief Commercial Officer, MRD Harlan Robins - Chief Scientific Officer Conference Call Participants Brian Weinstein - William Blair Elizabeth Webster - Gold ...

Adaptive Biotechnologies Corp (NASDAQ:ADPT) Q4 2021 Earnings Conference Call February 15, 2022 4:30 PM ET Company Participants Karina Calzadilla - VP, IR Chad Robins - Co-Founder, CEO & Chairman Kyle Piskel - Interim CFO & Principal Accounting Officer Harlan Robins - Co-Founder & Chief Scientific Officer Nitin Sood - Chief Commercial Officer Conference Call Participants Mark Massaro - BTIG Brian Weinstein - William Blair & Company Derik De Bruin - Bank of America Merrill Lynch Tejas Savant - Morgan Stanley ...